FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival

Byooviz Ranibizumab Biosimilar Approved; Company Reveals Launch Date Expectations

OK Sign Eye Woman
The FDA has approved the Byooviz ranibizumab biosimilar to Lucentis • Source: Alamy

More from Biosimilars

More from Products